Ongoing support Follow-ups, adjustments, and answers are available when you need them
Not for human or animal use
Ten patients received semaglutide 1.0 mg, and one patient each received semaglutide 0.5 mg, liraglutide 1.2 mg and liraglutide 2.4 mg (maximum tolerated dose)
A well-studied GIPR missense variant, E354Q (rs1800437), is associated with reduced BMI in large-scale GWAS and Mendelian randomization analyses
However, these cases are so rare that they will not affect our interpretation of the results [53]
We still need: Larger, long-term studies specifically focusing on psoriasis and PsA patients More data on optimal dosing and treatment duration Better understanding of how these drugs interact with current psoriasis and PsA treatments Empowering Your Psoriasis and PsA Management: Explore GLP-1 Options If you have psoriasis or PsA and struggle with weight management or treatment resistance, GLP-1 receptor agonists offer a new avenue for improving your condition